Form 4: MYGN COO Verratti Acquires Shares via PSU Vesting

Myriad Genetics Chief Operating Officer Mark Verratti acquired 32,810 shares of common stock through the vesting of performance-based restricted stock units.

Summary

• Mark Verratti, Chief Operating Officer of Myriad Genetics Inc. (MYGN), acquired 32,810 shares of common stock.
• The acquisition occurred on February 2, 2026, and was a result of the vesting of performance-based restricted stock units (PSUs).
• These PSUs were initially granted on March 15, 2023, and their final award amount was determined by the Compensation and Human Capital Committee based on the accomplishment of pre-determined performance metrics.
• Each PSU represents a contingent right to receive one share of the Company's common stock and will vest on March 15, 2026.
• Following this transaction, Mr. Verratti beneficially owns 414,636 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, reflecting the achievement of performance metrics and increased alignment of a key executive's interests with shareholders, though it's a routine compensation event.

Positives

• The Compensation and Human Capital Committee determined that pre-determined performance metrics were accomplished, leading to the vesting of PSUs.
• Increased beneficial ownership by a key executive (Chief Operating Officer) aligns management interests with shareholders.
• The acquisition of 32,810 shares at a price of $0 (as part of a compensation plan) indicates a significant increase in the executive's stake.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The acquired performance-based restricted stock units are scheduled to vest on March 15, 2026, indicating a future conversion of contingent rights into fully owned shares.

Management Comments

• The determination by the Compensation and Human Capital Committee that pre-determined performance metrics were accomplished implies management's successful execution against internal goals.

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly those tied to performance metrics, often signal management confidence in the company's strategic direction and operational execution within the competitive diagnostics and genetics industry. This transaction aligns the COO's incentives with long-term shareholder value creation.

Comparison to Industry Standards

• While specific comparable companies or projects are not detailed in this Form 4, the vesting of performance-based equity awards is a standard practice in executive compensation across the biotechnology and healthcare sectors, including companies like Illumina (ILMN) or Exact Sciences (EXAS), to incentivize long-term performance.
• The structure of PSUs, contingent on achieving specific performance metrics, is a common governance practice designed to link executive pay directly to company success, a benchmark for effective compensation strategies.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value due to higher insider ownership.
• Employees: Demonstrates the company's commitment to performance-based compensation, potentially motivating other employees.

Next Steps

• The 32,810 shares acquired from the PSUs are scheduled to vest on March 15, 2026.

Key Dates

Keywords

Myriad Genetics, MYGN, Mark Verratti, Insider Transaction, Form 4, Performance Stock Units, PSU Vesting, Executive Compensation, Stock Ownership